ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wolfson, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wolfson, P. J.
Related Collections
Right arrow History

Ann Thorac Surg 2003;76:S2224-S2229
© 2003 The Society of Thoracic Surgeons

Supplement: Gibbon & His Heart-Lung Machine

The development and use of extracorporeal membrane oxygenation in neonates

Philip J. Wolfson, MDa*

a Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania and Alfred I DuPont Hospital for Children, Wilmington, Delaware, USA

* Address reprint requests to Dr Wolfson, General Surgery, Alfred I. duPont Hospital for Children, 1600 Rockland Rd, Wilmington, DE 19899, USA
e-mail: p.wolfson{at}nemours.org

Presented at the symposium, "Gibbon & His Heart-Lung Machine: 50 Years & Beyond," Philadelphia, PA, May 2, 2003.

Abstract

Extracorporeal membrane oxygenation (ECMO) is the utilization of a modified heart-lung machine to provide temporary support for patients with severe respiratory or cardiac failure. In contrast to patients managed with traditional cardiopulmonary bypass, patients on ECMO undergo cannulation of relatively accessible blood vessels, are maintained at normal body temperature, and only require partial anticoagulation with heparin. Although first developed for use in adults, ECMO has been most successful in the treatment of newborn infants with life-threatening pulmonary failure. Since 1974, over 17,000 infants have received ECMO with a 78% survival rate. There is a 15%–20% incidence of neurodevelopmental disabilities among ECMO survivors.




This article has been cited by other articles:


Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
W. C. Oliver
Anticoagulation and Coagulation Management for ECMO
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2009; 13(3): 154 - 175.
[Abstract] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
S. Crow, A. C. Fischer, and R. M. Schears
Extracorporeal Life Support: Utilization, Cost, Controversy, and Ethics of Trying to Save Lives
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2009; 13(3): 183 - 191.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2003 by The Society of Thoracic Surgeons.